Seaport Res Ptn Comments on Hims & Hers Health, Inc.’s Q2 2024 Earnings (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) – Seaport Res Ptn upped their Q2 2024 EPS estimates for Hims & Hers Health in a research note issued on Monday, May 6th. Seaport Res Ptn analyst A. Kessler now forecasts that the company will post earnings per share of $0.05 for the quarter, up from their previous estimate of $0.02. Seaport Res Ptn currently has a “Buy” rating on the stock. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.11 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s FY2024 earnings at $0.19 EPS and FY2025 earnings at $0.37 EPS.

Several other analysts have also commented on HIMS. Citigroup boosted their price target on Hims & Hers Health from $12.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. TheStreet upgraded Hims & Hers Health from a “d” rating to a “c” rating in a research report on Monday, March 4th. Jefferies Financial Group restated a “hold” rating and issued a $15.00 target price (down from $17.00) on shares of Hims & Hers Health in a research note on Tuesday, April 16th. Canaccord Genuity Group initiated coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They issued a “buy” rating and a $20.00 target price for the company. Finally, Guggenheim raised their price target on shares of Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Moderate Buy” and an average target price of $15.07.

Hims & Hers Health Stock Down 1.5 %

Shares of HIMS opened at $12.16 on Wednesday. Hims & Hers Health has a 12 month low of $5.65 and a 12 month high of $17.16. The stock has a market cap of $2.61 billion, a price-to-earnings ratio of -107.91 and a beta of 0.97. The company has a 50-day moving average price of $14.01 and a two-hundred day moving average price of $10.39.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The business had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. During the same period in the prior year, the company posted ($0.05) earnings per share. Hims & Hers Health’s revenue was up 45.8% on a year-over-year basis.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently made changes to their positions in the stock. Graham Capital Management L.P. grew its holdings in shares of Hims & Hers Health by 39.4% during the 3rd quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock worth $2,141,000 after purchasing an additional 96,277 shares in the last quarter. Swiss National Bank increased its stake in Hims & Hers Health by 9.2% in the third quarter. Swiss National Bank now owns 309,200 shares of the company’s stock valued at $1,945,000 after acquiring an additional 26,100 shares during the last quarter. Vanguard Group Inc. lifted its stake in Hims & Hers Health by 3.1% during the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after purchasing an additional 428,671 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Hims & Hers Health by 11.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock valued at $3,551,000 after purchasing an additional 58,288 shares during the last quarter. Finally, Must Asset Management Inc. acquired a new position in shares of Hims & Hers Health during the 3rd quarter worth $1,596,000. 63.52% of the stock is currently owned by institutional investors.

Insider Activity at Hims & Hers Health

In related news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $14.97, for a total transaction of $2,827,653.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $14.97, for a total transaction of $2,827,653.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 4,080 shares of Hims & Hers Health stock in a transaction on Friday, February 9th. The shares were sold at an average price of $10.03, for a total transaction of $40,922.40. Following the completion of the sale, the insider now owns 154,345 shares in the company, valued at $1,548,080.35. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 736,191 shares of company stock valued at $9,733,700. 31.63% of the stock is owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.